Celebrating neuropathology's contributions to Alzheimer's Disease Research Centers

作者：D. Luke Fischer, Lea T. Grinberg, Jared T. Ahrendsen, Thomas G. Beach, Kevin F. Bieniek, Rudolph J. Castellani, Rati Chkheidze, Inma Cobos, Mark L. Cohen, John F. Crary, Dennis W. Dickson, Brittany N. Dugger, Sara Dunlop, Kurt Farrell, Bernardino Ghetti, Mohammad Haeri, William Harrison, Elizabeth Head, Annie Hiniker, Eric J. Huang, Anita Hüttner, Pouya Jamshidi, Alifiya Kapasi, C. Dirk Keene, Julia Kofler, Caitlin S. Latimer, Ann C. McKee, Karin Mente, Michael B. Miller, Thomas J. Montine, Meaghan Morris, Melissa E. Murray, Peter T. Nelson, Kathy L. Newell, Richard J. Perrin, Biswarathan Ramani, R. Ross Reichard, Subhojit Roy, Johannes C. M. Schlachetzki, William W. Seeley, Geidy E. Serrano, Salvatore Spina, Andrew F. Teich, Shih‐Hsiu J. Wang, Thomas Wısnıewskı, Edward B. Lee · 发表于：Alzheimer s & Dementia · 年份：2025 · DOI：10.1002/alz.70734 · 被引用次数：4 · 研究领域：Alzheimer's disease research and treatments、Dementia and Cognitive Impairment Research、Advanced Neuroimaging Techniques and Applications

Our understanding of Alzheimer's disease (AD) and related dementias (ADRD) has grown exponentially, thanks to significant investments by the National Institute on Aging (NIA). This article celebrates the 40th anniversary of the NIA's Alzheimer's Disease Research Centers, highlighting the pivotal role of neuropathology as the bedrock for neurodegeneration research. Neuropathology has championed the key principles of proteinopathy, selective vulnerability, and stereotypic spread. Furthermore, neuropathologic studies advanced our understanding of ADRD prevalence, heterogeneity, clinical-pathological correlations, and genetic underpinnings, spurring biomarker development for target engagement and disease monitoring. Disease-modifying therapies for AD were inspired and informed by neuropathology. The neuropathology community is poised to refine diagnostics, leveraging digital pathology and integrating genetics and pathomics to enhance subtyping for novel precision medicine approaches. Despite some common misconceptions and logistical challenges, neuropathology continues to be a critical component of the ADRD research infrastructure, serving as a key bridge between allied basic and clinical sciences. HIGHLIGHTS: We celebrate 40 years of NIA-funded ADRCs and their contributions through neuropathology studies that have significantly advanced our understanding and treatment of ADRD. Neuropathology uncovers principles of neurodegenerative disease: proteinopathy, selective vulnerability...